Navneet Majhail: Advances and practical application of precision medicine in oncology

Navneet Majhail shared a post on LinkedIn:

“On Sarah Cannon Cancer Network grand rounds today, it was great to hear insights from Vivek Subbiah and Andrew McKenzie about advances and practical application of precision medicine in oncology.

Thanks for sharing case studies that highlighted the incredible work Sarah Cannon Research Institute precision medicine team does in guiding their network oncologists and patients towards appropriate clinical trials and approved therapies.”

Vivek Subbiah replied saying:

“Such a delight to share the latest and greatest on Tumor Agnostic Precision Medicine and research conducted at Sarah Cannon Research Institute.

Thrilled to team tag with Andrew McKenzie on this interesting case based state-of-the-art updates. Thanks to the 150 + strong colleagues who attended the Sarah Cannon Cancer Network Grand rounds.

Thank you for the invite Dax Kurbegov and Navneet Majhail.”

Source: Navneet Majhail/LinkedIn and Vivek Subbiah/LinkedIn

Navneet Majhail, M.D., MS, FASTCT, is a Physician-in-Chief of Blood Cancers at the Sarah Cannon Transplant and Cellular Therapy Network. He is also the program medical director at the Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center in Nashville. His research centers on preventing and managing complications of blood and marrow transplantation, as well as health policy issues like disparities, quality of care, survivorship, and economic aspects of transplant.

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.